newsfilter
← Earnings
Earnings Releases·

ALX Oncology — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Cash, cash equivalents, and investments totaled $147.2 million as of September 30, 2026, up from $48.3 million as of December 31, 2025.
    • Cash and investments are sufficient to fund planned operations through the first half of 2028.
    • Research and development (R&D) expenses for the three months ended September 30, 2026, were $17.5 million, compared to $17.4 million in the prior-year period.
    • General and administrative (G&A) expenses for the three months ended September 30, 2026, were $5.5 million, an increase from $5.1 million in the prior-year period.
    • GAAP net loss for the three months ended September 30, 2026, was $21.8 million ($0.15 per share), compared to a net loss of $22.1 million ($0.41 per share) in the prior-year period.
    • Non-GAAP net loss for the three months ended September 30, 2026, was $18.9 million, compared to $19.6 million in the prior-year period.
    • For the nine months ended September 30, 2026, GAAP net loss was $57.7 million ($0.45 per share), compared to $78.8 million ($1.48 per share) in the prior-year period.
    • Total operating expenses for the nine months ended September 30, 2026, were $59.9 million, down from $81.0 million in the prior-year period.
    • Interest income for the nine months ended September 30, 2026, was $4.1 million, up from $3.4 million in the prior-year period.
    • Loss on debt extinguishment of $0.9 million was recorded in the nine months ended September 30, 2026, with no such loss in the prior-year period.
    • Total stockholders' equity was $125.9 million as of September 30, 2026, compared to $26.0 million as of December 31, 2025.
  • Guidance and Future Outlook:

    • Topline data from approximately 120 patients in the Phase 2 ASPEN-09-Breast clinical trial is expected in the second half of 2027.
    • Safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors are expected in December 2026.
    • A Key Opinion Leader (KOL) webinar is planned for December 2026 to review results from 35 patients enrolled in the ALX2004 Phase 1 study.
    • Management indicated multiple clinical catalysts are ahead and the company is well-positioned to create long-term value.
  • Business Segments and Product Lines:

    • Evorpacept: Data from the randomized Phase 2 ASPEN-06 trial was published in Nature Medicine, showing improved response rates versus control in HER2-positive gastric and gastroesophageal junction cancers, with the greatest benefit in patients with high CD47 expression.
    • Evorpacept: Enrollment in the ongoing Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy remains on track.
    • ALX2004: An ongoing Phase 1, first-in-human, open-label, multicenter trial is evaluating ALX2004 in patients with advanced or metastatic EGFR-expressing solid tumors.
    • ALX2004: The drug is an EGFR-targeted antibody-drug conjugate (ADC) utilizing a proprietary topoisomerase I inhibitor payload.
    • Regulatory Status: The FDA granted Fast Track designation to evorpacept for second-line treatment of HER2-positive gastric or GEJ carcinoma. Both the FDA and European Commission granted Orphan Drug Designation for this indication.
  • Market and Competitive Landscape:

    • Evorpacept is described as a potential best- and first-in-class CD47 checkpoint inhibitor and one of the most advanced to target the innate immune system.
    • Clinical studies across a wide spectrum of tumor types have included more than 750 patients to date.
    • The company is prioritizing evorpacept combinations in breast, gastric, and colon cancers.
  • Risks and Challenges:

    • Forward-looking statements involve substantial risks and uncertainties, including clinical trial results, regulatory approvals, and research and development costs.
    • Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other factors.
    • Risks are detailed in filings with the SEC, including Form 10-K and Form 10-Q.
  • Management Commentary and Tone:

    • CEO Jason Lettmann stated the company continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials.
    • Management highlighted the publication of ASPEN-06 results as reinforcing the promise of evorpacept and the biomarker-driven development strategy.
    • Management expressed confidence in the differentiated pipeline and disciplined execution to create long-term value for patients and shareholders.
  • Other Key Points:

    • CD47 expression is identified as a potential predictive biomarker for evorpacept efficacy.
    • R&D expense increases were driven by site activations and patient enrollment in ASPEN-09 and ALX2004 trials, headcount growth, and preclinical costs, offset by a $2.5 million development milestone met in the prior period.
    • G&A expense increases were driven by headcount growth and stock-based compensation, offset by decreases in corporate legal and consulting costs.
    • A lease termination gain of $0.2 million was recorded in the nine months ended September 30, 2026, compared to an impairment charge of $3.2 million in the prior-year period.
Company
ALX ONCOLOGY HOLDINGS INC
Sector
Healthcare
Industry
Biotechnology